ACTRN12618000505202进行中（未招募）3 期
Study of using Cyclophosphamide After Sibling-donor allogeneic stem-cell Transplantation (CAST) in patients with acute leukaemia and myelodysplasia: a randomised study comparing cyclosporin and methotrexate to cyclosporin and post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis.
Australasian Leukaemia and Lymphoma Group0 个研究点目标入组 134 人开始时间: 2018年4月6日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 134
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •18-70 years of age
- •Adult patients with AML/ALL in remission or MDS with <20% myeloblasts
- •Availability of 6/6-matched sibling donor
- •Adequate cardiac (LVEF greater than or equal to 40%), pulmonary (DLCO/VA >50%) and renal function (Creatinine Clearance greater than or equal to 60 ml/min).
排除标准
- •Donor other than a sibling
- •Graft source other than G-CSF mobilised PBSC
- •Use of in-vitro or in-vivo T-cell depletion
- •Life expectancy from co-morbid medical conditioning less than 12 months
- •Uncontrolled infection
研究者
相似试验
进行中（未招募）
2 期
Short treatment with the drug cyclophosphamide in bowel cancerStage II-IVA diagnosed colorectal cancerBowel cancerCancerISRCTN12508004Cardiff University500
进行中（未招募）
1 期
Graft-versus-host response after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantatioWomen and men with a hematologic malignancy for which a reduced-intensity conditioning allo-SCT is indicatedMedDRA version: 19.0Level: PTClassification code 10053239Term: Prophylaxis against graft versus host diseaseSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2016-002129-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)88
进行中（未招募）
不适用
Cyclophosphamide and Dexamethasone in combination with Ixazomib (ICD), in relpased or refractory multiple myeloma patients.Relasped and Refractory Mulitple MyelomaMedDRA version: 18.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2014-004511-36-GBniversity Of Leeds250
已完成
2 期
A parallel randomised phase II trial of cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP) chemotherapy with or without Bortezomib in relapsed mantle cell lymphomaRelapsed or refractory mantle cell lymphomaMantle cell lymphomaCancerISRCTN20159589Plymouth Hospitals NHS Trust (UK)90
招募中
2 期
A Phase II dose escalation study of cyclophosphamide in haematopoietic stem cell transplantation in severe systemic sclerosis patients unfit for standard dose cyclophosphamide.systemic sclerosisAutoimmune disorderACTRN12617000216314St Vincent's Hospital Sydney15